Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KTTFS
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
XMT-2056
|
|||||
| Synonyms |
XMT 2056; XMT-2056; XMT2056
Click to Show/Hide
|
|||||
| Organization |
Mersana Therapeutics, Inc.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 5 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
HT-19
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (HER2)
|
Antigen Info | ||||
| Payload Name |
STING agonist of XMT-2056
|
Payload Info | ||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Hydrophilic linker of XMT-2056
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
